13-valent pneumococcal conjugate vaccine (PCV13) is immunogenic and safe in children 6-17 years of age with sickle cell disease previously vaccinated with 23-valent pneumococcal polysaccharide vaccine (PPSV23): Results of a phase 3 study

Mariane De Montalembert, Miguel R. Abboud, Anne Fiquet, Adlette Inati, Jeffrey D. Lebensburger, Normeen Kaddah, Galila Mokhtar, Antonio Piga, Natasha Halasa, Baba Inusa, David C. Rees, Paul T. Heath, Paul Telfer, Catherine Driscoll, Sami Al Hajjar, Alberto Tozzi, Qin Jiang, Emilio A. Emini, William C. Gruber, Alejandra GurtmanDaniel A. Scott

Research output: Contribution to journal › Article › peer-review

30 Scopus citations

Fingerprint

Dive into the research topics of '13-valent pneumococcal conjugate vaccine (PCV13) is immunogenic and safe in children 6-17 years of age with sickle cell disease previously vaccinated with 23-valent pneumococcal polysaccharide vaccine (PPSV23): Results of a phase 3 study'. Together they form a unique fingerprint.

Medicine & Life Sciences